Table 3.
Time to progression and overall survival of patients treated with fulvestrant.
| TTP | OS | |||
|---|---|---|---|---|
| Variables | Months (95% CI) | p Value | Months (95% CI) | p Value |
| Overall | 8 (5.6–10.4) | 21 (16.0–26.0) | ||
| Primary resistance | 7 (2.8–11.2) | 0.098 | 32 (17.2–46.8) | 0.592 |
| Secondary resistance | 9 (6.1–11.9) | 21 (15.6–26.4) | ||
| Chemotherapy before fulvestrant | 6 (4.5–7.5) | 0.039 | 21 (10.7–31.3) | 0.519 |
| No chemotherapy before fulvestrant | 12 (8.7–15.3) | 21 (14.8–27.2) | ||
| Chemotherapy after fulvestrant | - | 34 (30.4–37.6) | <0.001 | |
| No chemotherapy after fulvestrant | - | 8 (4.2–11.8) | ||
| 50 or younger | 10 (4.5–15.5) | 0.829 | 32 (23.3–40.7) | 0.500 |
| 51 or older | 8 (5.9–10.1) | 21 (16.3–25.7) | ||
| Visceral Metastasis | 7 (5.1–8.9) | 0.142 | 18 (14.1–21.9) | 0.029 |
| No Visceral Metastasis | 11 (7.9–14.1) | 32 (23.0–41.0) | ||
| ≤2 previous therapies | 12 (9.4–14.6) | 0.015 | 26 (16.0–36.0) | 0.067 |
| ≥3 previous therapies | 6 (5.1–6.9) | 16 (10.5–21.5) | ||